Results for a Phase 2 clinical trial evaluating pembrolizumab in combination with magrolimab for relapsed or refractory Classic Hodgkin Lymphoma were posted on 2026-06-30. The study, which enrolled 8 participants, was terminated, with 3 participants achieving a complete response.
Background
Classic Hodgkin Lymphoma, particularly in its relapsed or refractory forms, represents a significant challenge in oncology. This study investigated the combination of pembrolizumab and magrolimab as a potential treatment strategy for these patients.
Trial design
The Phase 2 study (NCT04788043) was designed to evaluate the safety and efficacy of magrolimab in combination with pembrolizumab. The trial enrolled a total of 8 participants with relapsed or refractory Classic Hodgkin Lymphoma. The study was ultimately terminated.
Key results
For the 8 participants enrolled, the trial reported several key outcomes. Complete Response (CR) was observed in 3 participants. The Overall Response (OR) was reported as 6 participants in one measurement and 4 participants in another. Regarding safety, magrolimab-related adverse events were reported with counts of 70 events, 20 events, 6 events, 0 events, and 0 events across different outcome measurements.
What this means
The termination of this Phase 2 trial, despite some observed responses, indicates that the combination of pembrolizumab and magrolimab may not proceed further in this specific context for relapsed or refractory Classic Hodgkin Lymphoma. While 3 of 8 participants achieved a complete response, and overall responses were also noted, the termination suggests that the overall profile or objectives of the study were not met. The reported adverse event counts provide initial safety insights for the combination.
Source
The results for this clinical trial were posted on 2026-06-30 by ClinicalTrials.gov. Further details regarding the study (NCT04788043) are available on clinicaltrials.gov.